ARTICLE | Clinical News
TP10: Started Phase IIb trial
January 8, 2001 8:00 AM UTC
Avant Immunotherapeutics Inc. (AVAN), Needham, Mass. Product: TP10 Business: Cardiovascular Therapeutic category: Immune modulation Target: Complement Description: Soluble form of complement receptor...